S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.92 (+0.26%)
AAPL   181.57 (-0.52%)
MSFT   410.63 (+0.07%)
META   483.97 (-0.01%)
GOOGL   141.07 (-2.01%)
AMZN   175.44 (+0.26%)
TSLA   195.55 (+1.86%)
NVDA   798.08 (+1.26%)
NIO   5.63 (+4.26%)
AMD   177.84 (+0.75%)
BABA   76.14 (+0.24%)
T   16.75 (-0.30%)
F   12.15 (+0.08%)
MU   91.48 (+6.37%)
CGC   3.42 (+1.79%)
GE   154.30 (+0.63%)
DIS   108.15 (+0.38%)
AMC   4.51 (+1.58%)
PFE   27.37 (-1.40%)
PYPL   58.91 (-0.42%)
XOM   103.59 (-0.24%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.92 (+0.26%)
AAPL   181.57 (-0.52%)
MSFT   410.63 (+0.07%)
META   483.97 (-0.01%)
GOOGL   141.07 (-2.01%)
AMZN   175.44 (+0.26%)
TSLA   195.55 (+1.86%)
NVDA   798.08 (+1.26%)
NIO   5.63 (+4.26%)
AMD   177.84 (+0.75%)
BABA   76.14 (+0.24%)
T   16.75 (-0.30%)
F   12.15 (+0.08%)
MU   91.48 (+6.37%)
CGC   3.42 (+1.79%)
GE   154.30 (+0.63%)
DIS   108.15 (+0.38%)
AMC   4.51 (+1.58%)
PFE   27.37 (-1.40%)
PYPL   58.91 (-0.42%)
XOM   103.59 (-0.24%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.92 (+0.26%)
AAPL   181.57 (-0.52%)
MSFT   410.63 (+0.07%)
META   483.97 (-0.01%)
GOOGL   141.07 (-2.01%)
AMZN   175.44 (+0.26%)
TSLA   195.55 (+1.86%)
NVDA   798.08 (+1.26%)
NIO   5.63 (+4.26%)
AMD   177.84 (+0.75%)
BABA   76.14 (+0.24%)
T   16.75 (-0.30%)
F   12.15 (+0.08%)
MU   91.48 (+6.37%)
CGC   3.42 (+1.79%)
GE   154.30 (+0.63%)
DIS   108.15 (+0.38%)
AMC   4.51 (+1.58%)
PFE   27.37 (-1.40%)
PYPL   58.91 (-0.42%)
XOM   103.59 (-0.24%)
S&P 500   5,091.14 (+0.05%)
DOW   39,217.47 (+0.22%)
QQQ   437.92 (+0.26%)
AAPL   181.57 (-0.52%)
MSFT   410.63 (+0.07%)
META   483.97 (-0.01%)
GOOGL   141.07 (-2.01%)
AMZN   175.44 (+0.26%)
TSLA   195.55 (+1.86%)
NVDA   798.08 (+1.26%)
NIO   5.63 (+4.26%)
AMD   177.84 (+0.75%)
BABA   76.14 (+0.24%)
T   16.75 (-0.30%)
F   12.15 (+0.08%)
MU   91.48 (+6.37%)
CGC   3.42 (+1.79%)
GE   154.30 (+0.63%)
DIS   108.15 (+0.38%)
AMC   4.51 (+1.58%)
PFE   27.37 (-1.40%)
PYPL   58.91 (-0.42%)
XOM   103.59 (-0.24%)

Arrowhead Pharmaceuticals (ARWR) Earnings Date, Estimates & Call Transcripts

$32.01
+0.41 (+1.30%)
(As of 09:44 AM ET)

Earnings Summary

Upcoming
Earnings Date
May. 7Estimated
Actual EPS
(Feb. 6)
-$1.24 Missed By -$0.46
Consensus EPS
(Feb. 6)
-$0.78
Skip Charts & View Estimated and Actual Earnings Data

ARWR Earnings Estimates and Actuals by Quarter

The chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.

ARWR Estimated and Actual Revenue by Quarter

The chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter.

Arrowhead Pharmaceuticals Analyst EPS Estimates

QuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateCompany Guidance
Q1 20243($1.00)($0.29)($0.62) 
Q2 20244($1.17)($0.24)($0.59) 
Q3 20244($1.20)($0.24)($0.70) 
Q4 20244($1.33)$0.31($0.60) 
FY 202415($4.70)($0.46) ($2.50)

ARWR Earnings Date and Information

Arrowhead Pharmaceuticals last released its earnings results on February 6th, 2024. The biotechnology company reported ($1.24) earnings per share for the quarter, missing analysts' consensus estimates of ($0.78) by $0.46. The business had revenue of $3.55 million for the quarter, compared to the consensus estimate of $35.60 million. Its revenue was down 94.3% on a year-over-year basis. Arrowhead Pharmaceuticals has generated ($2.78) earnings per share over the last year (($2.78) diluted earnings per share). Earnings for Arrowhead Pharmaceuticals are expected to grow in the coming year, from ($2.70) to ($2.53) per share. Arrowhead Pharmaceuticals has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 7th, 2024 based off prior year's report dates.

Arrowhead Pharmaceuticals Earnings History by Quarter

DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueCall Transcript
5/7/2024
Estimated)
------- 
2/6/2024Q1 2024($0.78)($1.24)($0.46)($1.24)$35.60 million$3.55 million    
11/29/2023Q4 2023($0.70)($1.03)($0.33)($1.03)$38.87 million$16.10 million
8/7/2023Q3 2023($0.58)($0.96)($0.38)($0.96)$45.42 million$15.83 million    
5/2/2023Q2 2023($0.65)$0.45+$1.10$0.45$45.48 million$146.27 million    
2/6/2023Q4 2022$1.14($0.39)($1.53)($0.39)$162.52 million$62.55 million    
11/28/2022Q4 2022($0.57)($0.81)($0.24)($0.81)$107.60 million$31.58 million
8/4/2022Q3 2022($0.45)($0.68)($0.23)($0.68)$52.61 million$32.41 million    
5/10/2022Q2 2022$0.39$0.41+$0.02$0.41$122.15 million$151.80 million    
2/2/2022Q1 2022($0.22)($0.60)($0.38)($0.60)$67.30 million$27.44 million    
11/22/2021Q3 2021$0.04($0.61)($0.65)($0.61)$79.31 million$38.28 million    
8/4/2021Q2 2021($0.08)($0.29)($0.21)($0.29)$50.20 million$45.89 million    
5/3/2021Q1 2021($0.09)($0.26)($0.17)($0.26)$39.42 million$32.81 million  












Arrowhead Pharmaceuticals Earnings - Frequently Asked Questions

When is Arrowhead Pharmaceuticals's earnings date?

Arrowhead Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 7th, 2024 based off last year's report dates. Learn more on ARWR's earnings history.

Did Arrowhead Pharmaceuticals beat their earnings estimates last quarter?

In the previous quarter, Arrowhead Pharmaceuticals (NASDAQ:ARWR) missed the analysts' consensus estimate of ($0.78) by $0.46 with a reported earnings per share (EPS) of ($1.24). Learn more on analysts' earnings estimate vs. ARWR's actual earnings.

How can I listen to Arrowhead Pharmaceuticals's earnings conference call?

The conference call for Arrowhead Pharmaceuticals's latest earnings report can be listened to online. Listen to Conference Call

How can I read Arrowhead Pharmaceuticals's conference call transcript?

The conference call transcript for Arrowhead Pharmaceuticals's latest earnings report can be read online. Read Transcript

How much revenue does Arrowhead Pharmaceuticals generate each year?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded annual revenue of $181.74 million.

How much profit does Arrowhead Pharmaceuticals generate each year?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) has a recorded net income of -$205.27 million. ARWR has generated -$2.78 earnings per share over the last four quarters.

What is Arrowhead Pharmaceuticals's EPS forecast for next year?

Arrowhead Pharmaceuticals's earnings are expected to grow from ($2.70) per share to ($2.53) per share in the next year.


More Earnings Resources from MarketBeat

This page (NASDAQ:ARWR) was last updated on 2/26/2024 by MarketBeat.com Staff